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Clinical Infectious Diseases
BBRRI IEEFF RREEPPOORRTT

Catherine Liu,1,2, Luke Strnad,3,4 Susan E. Beekmann,5,6 Philip M. Polgreen,5,6 and
Henry F. Chambers7

survey (Supplementary Materials) to assess adult ID specialist
opinions and practice patterns in the management of SAB.
The EIN distributed the survey via emailed weblink or facsimile on 5 January 2017. Two reminders at 1-week intervals
were provided. Survey responses were analyzed using SAS
version 9.4. A P value of < .05 was considered statistically
significant.
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Infectious disease management of Staphylococcus aureus bacteremia (SAB) was surveyed through the Emerging Infections
Network. Although there were areas of consensus, we found
substantial practice variation in diagnostic evaluation and management of adult patients with SAB. These findings highlight
opportunities for further research and guidance to define best
practices.
Keywords. Staphylococcus aureus; bacteremia; infectious
disease physicians.
Staphylococcus aureus bacteremia (SAB) is associated with high
morbidity, mortality, and healthcare costs [1]. Infectious disease
(ID) consultation for SAB has been associated with significant
improvement in patient outcomes and increased adherence to
best practices in SAB management such as follow-up blood
cultures, echocardiography, source identification/control, and
appropriate antibiotic therapy [2, 3]. However, little is known
about practice patterns among ID physicians in scenarios where
data are limited or inconclusive. We distributed a survey to
members of the Emerging Infections Network (EIN) to assess
physician practices in the management of SAB.
METHODS

The Infectious Diseases Society of America’s (IDSA) EIN is
a network of practicing ID physicians in the United States
and Canada, funded by the Centers for Disease Control and
Prevention [4]. We developed an 11-question multiple-choice
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RESULTS
Characteristics of Participants

Of 1286 active EIN physician members with an adult ID practice, 723 (56%) responded to this survey. Respondents (220/723
[30%]) were more likely than nonrespondents (117/563 [21%])
to have ≥25 years of ID experience (P < .0001). No other significant differences were identified. Baseline practice characteristics including clinical experience, practice type, and geographic
location are provided in Supplementary Table 1. Fifty-four (7%)
respondents did not manage SAB and opted out.
Diagnostic Evaluation of SAB

Repeat blood cultures and echocardiography are performed
by the majority of respondents (Figure 1A). Most (599/667
[90%]) indicated they would always perform a transthoracic
echocardiogram (TTE). Those with <15 years of experience were more likely to always do a TTE (93% vs 86%;
P = .01). A transesophageal echocardiogram (TEE) would be
performed on every patient with a negative TTE by 126 (19%)
of respondents whereas 473 (71%) would only perform TEE
under selected circumstances (Figure 1B). Those practicing in
the Midwest, Northeast, or South [5] regions were more likely
to always perform a TEE compared to those in the West or
Canada/Puerto Rico (24% vs 11%; P = .009).
Nafcillin or Cefazolin for Methicillin-susceptible Staphylococcus aureus
Endocarditis

For treatment of left-sided methicillin-susceptible S. aureus
(MSSA) endocarditis without CNS involvement, 32% chose
cefazolin and 29% favored nafcillin, whereas 32% considered
the 2 equivalent. Among the 215 who chose cefazolin, 207 provided a rationale, with most citing a combination of equal efficacy, less toxicity, dosing convenience, and cost. Among the
193 who selected nafcillin, 169 provided a rationale, with most
citing nafcillin as the “gold standard,” whereas others favored
it due to inoculum effect or better CNS penetration for clinically silent disease. Those with <5 (vs ≥5) years of experience
were more likely to use cefazolin (39% vs 33%) whereas those
with ≥15 (vs <15) years of experience were more likely to use
nafcillin (37% vs 26%) (P = .048).
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Figure 1. Practice patterns among survey respondents on the diagnostic evaluation and management of Staphylococcus aureus bacteremia (SAB). A, Diagnostic
workup routinely performed in the evaluation of a patient with SAB. B, Respondents
indicating they would perform transthoracic echocardiogram (TTE) on every patient
but only perform transesophageal echocardiogram (TEE) under these selected
circumstances (n = 473). C, Management of patient with methicillin-resistant
Staphylococcus aureus endocarditis and persistent SAB on day 6 of vancomycin,
with therapeutic trough and vancomycin MIC of .5 mg/L. D, Factors influencing
decision to extend duration of therapy from 2 weeks to 4–6 weeks assuming
negative echocardiography (TTE and/or TEE). Abbreviations: Abd, abdominal; cx,
culture; CT, computed tomography; MRI, magnetic resonance imaging; MRSA,

Duration of Therapy

Most respondents managed SAB with at least 14 days of intravenous (IV) antibiotics in several scenarios. In a patient with
MRSA bacteremia and a skin and soft tissue source, rapid clearance of blood cultures, negative TTE, and no evidence of metastatic infection, most (491/669 [73%]) would treat with IV
vancomycin for 14 days whereas 87 (13%) transitioned to oral
antibiotics to complete a 14-day course. A minority (24/669
[4%]) would treat for 5–7 days with either oral or IV antibiotics
while 47 (7%) favored a longer duration of 21–28 days.

methicillin-resistant Staphylococcus aureus; TEE, transesophageal echocardiogram;
TTE, transthoracic echocardiogram. *Among 222 respondents who commented on
other clinical factors that would prompt TEE, common responses included presence
of cardiac device or prosthetic valve (58 [26%]); clinical suspicion for infective endocarditis including embolic phenomenon or metastatic infection (43 [19%]); or TEE
results would change management (eg, duration of therapy, surgical management)
(36 [16%]).
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When managing a patient with methicillin-resistant S. aureus (MRSA) bacteremia and a vancomycin minimum inhibitory concentration (MIC) of 2 mg/L, a majority (336/665
[51%]) of respondents would treat with vancomycin if clinically responding, whereas 248 (37%) favored daptomycin
and 29 (4%) chose ceftaroline. Less than 1% of respondents
selected linezolid, telavancin, trimethoprim-sulfamethoxazole,
or daptomycin plus ceftaroline. Respondents in a university or
teaching hospital were more likely to use vancomycin compared
with those in a community or Veterans Affairs/Defense
Department hospital (55% vs 43%; P = .03).
In a patient with MRSA endocarditis and persistent bacteremia on day 6 of vancomycin, most (504/668 [75%]) would
modify therapy. Alternative monotherapy was selected by
245 (37%) respondents whereas 215 (32%) favored combination therapy (Figure 1C). Among those who chose another
single agent, 193 (78%) selected daptomycin while 36 (15%)
chose ceftaroline. The specific combination of daptomycin and
ceftaroline was chosen by 66 (10%). Those practicing in the
Midwest were most likely to choose alternative monotherapy
(62%). Those in the Northeast and West were most likely to use
combination therapy with daptomycin (28%; P = .04), and were
more likely to use daptomycin and ceftaroline (15%) compared
to those in the Midwest (5%) and South (7%) (P = .004).
The daptomycin dose used for MRSA bacteremia varied, with
38%, 43%, and 17% of respondents selecting 6 mg/kg, 8 mg/kg,
and 10–12 mg/kg, respectively. Doses of 10–12 mg/kg were
most likely to be used in the Northeast and West (21% and 20%,
respectively), while 6–8 mg/kg was most likely to be used in the
Midwest (91%) (P = .0002).

Management of Septic Thrombophlebitis

Most
respondents
(467/657
[71%])
recommended
anticoagulation in the setting of SAB and peripherally inserted
central catheter–associated deep vein thrombosis after catheter
removal. Duration of antimicrobial therapy varied with 52% of
respondents treating for 4 weeks while 19% chose 2 weeks and
25% chose 6 weeks.
DISCUSSION

SAB is a serious disease commonly managed by ID physicians.
Most respondents performed repeat blood cultures and echocardiography, and treated with IV therapy for at least 14 days.
There were some areas of consensus, but this survey highlights
considerable practice variation among respondents representing
a wide breadth of ID practitioners in North America, including
differences by years of experience, geographic region, and practice environment.
The IDSA MRSA treatment guidelines recommend echocardiography in all patients with SAB, with TEE being the preferred modality due to its greater sensitivity [6]. Although the
vast majority of respondents supported TTE as part of the diagnostic evaluation of SAB, only 19% of respondents indicated
they would always perform a TEE. These findings are consistent
with other studies that suggest routine use of TEE is infrequent
[7]. TEE is an invasive procedure that has complication risks, is
resource intensive, and may not be available at all centers. Some
studies suggest that TEE may not be necessary for all cases of
SAB and that clinical prediction rules may help with risk stratification, but these require external validation [8]. The lack of
concordance between guideline recommendations and current
practice indicates a need for further research and guidance on
the role of TEE among patients with SAB.
There was lack of consensus regarding the treatment of
MSSA endocarditis, with respondents almost evenly distributed among cefazolin, nafcillin, or use of either drug,
suggesting the need for evidence-based guidelines to define
optimal therapy. Those with fewer years of experience favored cefazolin whereas more experienced clinicians preferred nafcillin. These differences may reflect a growing body
532 • cid 2019:69 (1 August) • BRIEF REPORT

of literature suggesting similar clinical outcomes and fewer
drug-related adverse events with the use of cefazolin for MSSA
bacteremia [9]. However, early reports of cefazolin treatment
failure in the setting of endocarditis have led others to caution
its use in high-inocula infections [10].
Although the presence of prosthetic devices or positive repeat blood cultures would prompt most to extend therapy to
4–6 weeks, a smaller proportion of respondents were influenced
by immunosuppression, diabetes, or community-onset bacteremia. Further guidance is needed to identify patients who are
at increased risk of relapse or serious complications, in whom
prolonged treatment duration may be warranted.
Consistent with guideline recommendations [6], clinical
response influenced 51% of respondents to continue vancomycin in a patient with MRSA bacteremia and vancomycin
MIC of 2 μg/mL, although a substantial portion would switch
to daptomycin. Observational studies examining the role of
daptomycin vs vancomycin in management of MRSA bacteremia with high vancomycin MICs have yielded mixed results
[11, 12], and a randomized controlled trial designed to evaluate this issue was recently terminated due to slow accrual [11].
Although 8 mg/kg was the most commonly selected dose of
daptomycin, a sizable minority chose the US Food and Drug
Administration label dose of 6 mg/kg for management of MRSA
bacteremia. The substantial differences in management of the
above scenario and treatment of persistent bacteremia highlight
the lack of high-quality evidence in these areas.
Our study has several limitations. As with all voluntary
surveys, selection bias could yield results not generalizable to
all ID specialists. Response bias is possible and survey answers
may not accurately reflect clinical practice. Although the value
of ID consultation in SAB management has been established by
multiple studies, this survey demonstrates that there remains
ample opportunity to further define best practices and optimize
management of this complex disease.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online.
Consisting of data provided by the authors to benefit the reader, the posted
materials are not copyedited and are the sole responsibility of the authors,
so questions or comments should be addressed to the corresponding author.
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In a patient with 1 of 2 blood cultures positive for MSSA,
no obvious signs or symptoms of infection, a normal white
blood cell count, negative repeat blood cultures, negative TTE,
and no evidence of metastatic infection, most (445/664 [67%])
respondents would treat with IV antibiotics for 14 days whereas
51 (8%) would treat for 4–6 weeks. A minority (10%) would
consider the cultures a contaminant and stop antibiotics.
Most respondents would extend treatment duration to 4–6
weeks in the setting of SAB and a negative echocardiogram
for patients with a prosthetic device or positive repeat blood
cultures (Figure 1D).
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